The policy landscape is changing in ways that could materially affect patient access, provider revenue, and payer strategies.
Two trends stand out: stronger efforts to lower prescription drug costs and expanded support for telehealth.
Together they influence affordability, access, and how care is delivered across the country.
Prescription drug pricing: what’s changing and why it matters
Policymakers and regulators are pursuing multiple levers to reduce out-of-pocket costs and overall drug spending.
Key approaches gaining traction include:
– Negotiation and price reviews: Lawmakers and agencies are supporting mechanisms that allow public payers to negotiate or review prices for select high-cost medicines. Negotiation aims to bring prices closer to market value, especially for drugs with little competition.
– Inflation-based rebates and caps: Programs that penalize price increases above inflation are encouraging manufacturers to hold price growth in check and protect patients from sudden cost spikes.
– PBM transparency and oversight: Reforms targeting pharmacy benefit managers seek clearer reporting on rebates, spread pricing, and pass-through arrangements so insurers and employers better understand how savings are shared.
– Boosting competition: Policies that streamline generic and biosimilar entry — reducing regulatory barriers and accelerating approvals — are intended to increase competition and lower prices for commonly used therapies.
– Targeted affordability programs: Expansion of affordability assistance and redesign of cost-sharing structures can reduce financial strain for patients with chronic conditions who rely on expensive medications.
These measures can shift incentives across the pharmaceutical supply chain. Providers may need to adapt prescribing behavior toward cost-effective alternatives when clinically appropriate, and payers will re-examine formulary designs to balance access and budgetary targets.
Telehealth: from emergency experiment to a stable element of care
Telehealth has moved beyond a temporary fix and is being integrated into mainstream delivery through policy actions that address reimbursement, licensure, and infrastructure:
– Payment parity and flexibility: Many payers and regulators are expanding coverage and reimbursement for virtual visits, including behavioral health and chronic care management. This makes telehealth a financially viable option for more providers.
– Cross-state practice: Licensure compacts and interstate agreements are easing barriers for clinicians caring for patients across state lines, improving access in underserved regions.
– Broadband and digital equity: Investments in broadband expansion and device access aim to reduce the digital divide that limits telehealth use among rural and low-income populations.
– Privacy and standards: Updated guidance clarifies privacy expectations for telehealth platforms and encourages secure technologies that comply with federal protections.
Adoption of virtual care is particularly transformative for mental health, primary care follow-ups, and remote monitoring for chronic disease.
Providers can maintain continuity of care while reducing travel time and no-show rates.
What providers, patients, and policymakers should focus on now
– Providers: Review prescribing patterns and stay informed about formulary changes and biosimilar options. Integrate telehealth strategically for chronic disease management and behavioral health.
– Patients: Ask clinicians about lower-cost therapeutic alternatives and financial assistance programs. Confirm telehealth availability and whether visits are covered by your insurer.
– Policymakers: Monitor outcomes data to ensure reforms improve affordability without undermining innovation.
Prioritize digital equity so telehealth expands access broadly.
Takeaway: Coordinated policy changes around drug pricing and telehealth have the potential to improve affordability and access while reshaping care delivery. Success depends on aligning incentives across payers, providers, and manufacturers, and ensuring that new tools reach the patients who need them most.